-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2341 Racial Disparities in Survival Outcomes of Diffuse Large B Cell Lymphoma: A Retrospective Cohort Study from 2000 to 2021

Program: Oral and Poster Abstracts
Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
Hematology Disease Topics & Pathways:
Fundamental Science, Research, Translational Research
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Oboseh John Ogedegbe, MD1*, Asfand Yar Cheema, MD2*, Ahmed Bashir Sukhera, MD3*, Gloria Erazo, MD3*, Jorge Rodriguez Vazquez, MD3*, Serhan Unlu, MD4 and Tabowei Godfrey5*

1Trinity Health Ann Arbor Hospital, Ypsilanti, MI
2Tauusig Cancer Institute, Cleveland Clinic, Cleveland
3Department of Internal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, Odessa, TX
4Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Texas Tech University Health Science, Permian Basin, Odessa, TX

Introduction
Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for 25-30% of all cases of NHL. DLBCL is an aggressive disease that can be cured in up to 50% of the patients who achieve complete remission following treatment with first-line therapy.
In this study, we described the effect of race/ethnicity on survival outcomes among patients with DLBCL in the United States.

Methods
We extracted data on patients with a primary diagnosis of DLBCL from the Surveillance, Epidemiology and End Results (SEER) Registry. These patients had a primary diagnosis of DLBCL. We excluded patients with missing or unknown deaths, and Kaplan-Meier methods were used to estimate 5-year survival rates. Cox proportional hazards regression was used for multi-variable modelling of the survival database. The difference between the observed number of events between each group was compared using a log-rank statistical test.

Results
Our analysis revealed 99,415 patients with DLCBL. 82.8% (82,356) of patients were white, 7.2% (7244) of patients were black, 0.6% (602) were American Indian/Alaska Native, and 9.3% (9213) were Asian or Pacific Islanders. The one and five-year survival by race/ethnicity was White (75.9%, 64.0%), Black (72.6%, 60.6%), American Indian/Alaska Native (72.6%,61.1%) and Asian/Pacific Islander (76.5%,63.5%). Race/ethnicity proved to be a predictor of worse outcomes, with Asian/Pacific Islander HR 0.96 (95% CI; 0.92-0.99, p = <0.001), Black HR 1.01 (95% CI; 0.98-1.04, p = 0.629), American Indian/Alaska Native HR 1.06 (95% CI; 0.95-1.18, p = 0.294). There was no survival disparity by sex, male, HR 1.00 (0.98-1.02) p = 0.93.

Conclusion
Race plays a significant role in survival outcomes, with certain races associated with improved outcomes in patients with DLBCL. Asian/Pacific Islanders demonstrated a statistically significant improved survival outcome compared to whites. Of note, there was no disparity in survival outcomes by sex.

Disclosures: No relevant conflicts of interest to declare.

See more of: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
See more of: Oral and Poster Abstracts
<< Previous Abstract | Next Abstract >>
*signifies non-member of ASH